Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

摘要

Background This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. Methods A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. Results Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p?=?0.007) and a lower risk of hospitalization (HR 0.787, p?=?0.02) compared to treatment with decitabine. Conclusions This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.